Contribute Try STAT+ Today

WASHINGTON — The drug industry’s lobbying group is calling on its lobbyists to push back on a potential budget deal that reportedly includes drug pricing reforms that will cost the industry $115 billion.

In an email sent Thursday night to lobbyists both inside and outside the organization and obtained by STAT, PhRMA urged its small army of advocates to do all they can to block the potential deal, which is quickly becoming intertwined with a must pass, multibillion-dollar budget deal.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.